Galectin Therapeutics jumps after positive data from its melanoma treatment.

H.C. Wainwright reduced Galectin Thereapeutics' (GALT) stock rating to 'neutral' after the company's fatty liver disease drug failed in a phase II clinical trial.

Galectin Therapeutics' (GALT) stock rating was cut two notches to 'sell' at Roth Capital on Wednesday after the company's drug for fatty liver disease failed a clinical trial.

Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?

These under-$10 stocks look ready to break out and trade higher from current levels.

Galectin Therapeutics (GALT) plummeted Tuesday after the company reported poor results in an early-stage trial of its experimental drug for treatment of a fatty liver disease.

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.

Shares of drugmaker Intercept Pharmaceuticals (ICPT) are climbing after research firm Summer Street initiated coverage of the shares with a Buy rating and a $650 price target in a note to investors earlier today.

U.S. retirees may get a big benefit with the next Social Security cost-of-living adjustment for 2023.

Restaurants are moving to adapt to customers with very different wants and desires.

E-commerce giant Amazon is the subject of a major investigation linked to its Prime service. It's not sitting idly by.